[Blog] Who's funding stem cell research?
By Jim Fossett,
Bioethics.net
| 08. 14. 2007
We've been arguing for a long time here that states have been spending more on human embryonic stem cell(hESC) research than the feds, and now we have some numbers to back it up. In a piece just posted on the Rockefeller Institute of Government website, we try to tote up who's spending how much on stem cell research in general and hESC in particular. While we can't be nearly as precise as we'd like, several things are clear..
+ The feds aren't spending much at all. Total stem cell allocations via NIH has been roughly flat at $640 million annually for the last couple of years. Only about six percent of that, or roughly $40 million annually, goes for hESC research.
+ States are spending more than the feds on hESC. California by itself has already obligated more than $200 million to hESC research, making it the largest hESC funder in the world. The California Institute of Regenerative Medicine (CIRM), the state agency which manages the stem cell program, is spending more than five times what NIH is spending...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
